Schlackow I, et al. - Researchers evaluated the impact of statins and ezetimibe on quality-adjusted life years (QALYs) and health care costs in the patients with non-dialysis-dependent chronic kidney disease (CKD) in the United States (US) and the United Kingdom (UK), by using the Study of Heart and Renal Protection (SHARP) CKD-CVD (cardiovascular disease) policy model. They defined cost-effectiveness as net costs below $100,000/QALY (US) or £20,000/QALY (UK). In non-dialysis patients with stages 3B to 5 CKD in the US, an increase in life expectancy by 0.23 to 0.31 QALYs was noted with atorvastatin 40 mg ($0.103/day as of January 2019), at a net cost of $20,300 to $78,200/QALY. With the addition of ezetimibe 10 mg ($0.203/day), an increase in life expectancy by an additional 0.05 to 0.07 QALYs was reported, at a net cost of $43,600 to $91,500/QALY. Overall, statin/ezetimibe combination therapy was cost-effective in attenuating CVD risk in patients with non-dialysis-dependent CKD.